Formulation, development and evaluation of meclizine HCL transdermal patches

This work used a solvent evaporation approach with polyethylene glycol (PEG 400) as a plasticizer to develop a transdermal patch with meclizine Hcl using varying ratios of hydrophilic and hydrophobic polymeric systems. FT-IR spectroscopy research was used to examine the drug's and the polymers' physicochemical compatibility. The physicochemical characteristics, skin irritation, in vitro drug release, ex-vivo permeation investigations across rat abdomen skin, and stability studies of the developed patches were assessed. The medication and the polymers utilised did not interact, according to the findings of FT-IR investigations. The physicochemical parameters of each formulation were consistent. Franz diffusion cells were used to conduct in vitro permeation tests of the formulations. Formulation F3 adhered to Fick's diffusion process and demonstrated superior penetration through rat skin (8527.5±1.25μg/cm2 /hr) in comparison to the other formulations. Formulation F3, which contains the polymeric blend 19:1 Hydroxypropylmethyl Cellulose (HPMC E 50cps: Eudragit RL 100), has demonstrated optimal release when compared to other formulations and demonstrated high physical stability based on in-vitro drug release and ex-vivo skin penetration performance. Further in-vivo tests were necessary, although it has been shown that meclizine Hcl can be constructed as a matrix type transdermal drug delivery system (TDDS).